Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use.
The ability of glycosaminoglycans to bind to a wide number of biologically active macromolecules has already been investigated . Recent clinical trials on the possible therapeutic benefits of glycosaminoglycans must be placed in perspective , even if they appear to be particularly encouraging , especially as regards the glycosaminoglycan effects on certain coagulation factors . A multicenter , medium-term , double-blind , crossover trial was performed by several Italian Lipid Clinics to determine whether administration of a medium molecular weight glycosaminoglycan ( Sulodexide ) has a significant clinical effect . Patients affected by peripheral vascular disease and /or hyperlipidemia ( type IIa , IIb and IV ) were su bmi tted to a 4-week wash-out period , followed by parenteral Sulodexide ( S ) or placebo ( P ) administration for 2 weeks , another 2 week wash-out period , parenteral crossover drug or P administration for 2 weeks and , finally , oral S administration for 6 months . Sulodexide lowered plasma viscosity and plasma fibrinogen in all patients . There was also a drop in triglycerides together with a rise in apo A-I and HDL-C in type IV hyperlipoproteinemics , whereas there was no significant effect on total or LDL-plasma cholesterol in type IIa and IIb patients . Moreover , there was a percent increase in peak flow and rest flow in the lower limbs of peripheral vascular disease patients . No side effects or intolerance phenomena were detected . The results indicate that Sulodexide administration may be useful in long-term treatment of patients with peripheral vascular disease and a concomitant increase in plasma triglycerides and /or fibrinogen and /or viscosity
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .